Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: a prospective cohort study

dc.contributor.authorNicolás, David
dc.contributor.authorSuárez, Antonio
dc.contributor.authorAmbrosioni, Juan
dc.contributor.authorManzardo, Christian
dc.contributor.authorLigero, Carmen
dc.contributor.authorCosta, Josep
dc.contributor.authorFernández, Emma
dc.contributor.authorMarcos, Ma. Angeles
dc.contributor.authorPlana Prades, Montserrat
dc.contributor.authorMosquera, Maria Mar
dc.contributor.authorSánchez-Palomino, Sonsoles
dc.contributor.authorGatell, José M.
dc.contributor.authorMiró Meda, José M. (José María), 1956-
dc.date.accessioned2020-05-19T21:16:50Z
dc.date.available2020-05-19T21:16:50Z
dc.date.issued2019-08-03
dc.date.updated2020-05-19T21:16:50Z
dc.description.abstractBackground: Severe cases of primary HIV infection have been described in patients presenting with neurological involvement, AIDS defining events or other life-threatening events. These severe forms have not been fully studied. Objectives: To determine the prevalence and characteristics of severe PHI in a hospital-based cohort of primary HIV infection, and the response to the early initiation of antiretroviral therapy (ART) at 12 months. Methods: Every patient with PHI attending Hospital Clínic of Barcelona (1997-2015) was evaluated. Severe PHI was defined using clinical, analytical and immunological criteria. Chi-squared test was used for categorical variables and Student's t-test for quantitative variables. Results: 33% of 224 PHI patients (95% CI: 26.84%-39.16%) had a severe PHI. These patients had more symptoms, abnormal analytical parameters and hospital admissions. The severe PHI group had a significantly higher viral load although no differences were observed at 12 months in terms of viral suppression or CD4 count recovery. None died during PHI. Conclusions: Up to one third of patients in our cohort presented with a severe PHI, which was associated with higher hospitalization rates and higher plasma HIV RNA viral load. However, severe forms were not associated to a worse clinical, immunological or virological outcome at 12 months.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec691892
dc.identifier.issn1201-9712
dc.identifier.urihttps://hdl.handle.net/2445/161478
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.ijid.2019.08.001
dc.relation.ispartofInternational Journal of Infectious Diseases, 2019, vol. 88, p. 73-79
dc.relation.urihttps://doi.org/10.1016/j.ijid.2019.08.001
dc.rightscc-by-nc-nd (c) Nicolás, David et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.sourceArticles publicats en revistes (Fonaments Clínics)
dc.subject.classificationInfeccions per VIH
dc.subject.classificationPacients amb lesions cerebrals
dc.subject.classificationAntiretrovirals
dc.subject.otherHIV infections
dc.subject.otherBrain damage patients
dc.subject.otherAntiretroviral agents
dc.titlePrevalence, clinical characteristics and outcome of severe primary HIV-1 infection: a prospective cohort study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
691892.pdf
Mida:
762.12 KB
Format:
Adobe Portable Document Format